.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 4,401,662

« Back to Dashboard

Details for Patent: 4,401,662

Title: Oligosaccharides having anti-Xa activity and pharmaceutical compositions containing them
Abstract:Oligosaccharides obtainable from heparin including heparinic constituents of molecular weights ranging from 2000 to 50,000. Said fractions have a Yin-Wessler titer and a USP titer in a ratio of at least 30. They consist of chains constituted by no more than 8 saccharidic moities. They possess a strong antithrombotic activity and are then useful as antithrombotic drugs.
Inventor(s): Lormeau; Jean-Claude (Maromme la Maine, FR), Choay; Jean (Paris, FR), Petitou; Maurice (Paris, FR)
Assignee: Choay, S.A. (Paris, FR)
Filing Date:Oct 06, 1980
Application Number:06/194,545
Claims:1. An oligosaccharide fraction of the heparin chain which oligosaccharide has improved antithrombotic activity in vivo higher than that of heparin (as measured by the Yin-Wessler test), which oligosaccharide fraction (1) comprises not more than 8 saccharide units, (2) of which one is an N-sulfate-3-O-sulfate-D-glucosamine unit (3) has anti-Xa activity at least 10 times that of heparin, (4) specific affinity for AT III, (5) a ratio of Yin-Wessler titer to USP titer of at least 30 and (6) virtually no anticoagulant activity (as determined by the USP test) and, the biologically acceptable salts of said oligosaccharide.

2. The oligosaccharide of claim 1 which oligosaccharide contains a saccharide sequence of units selected from the group consisting of ABCDEFGH, ABGHCDEF, ABCDEF, CDEFGH and DEFGH, wherein A, B, C, D, E, F, G and H are defined as follows

A=unsaturated or saturated uronic acid

B=N-sulfate-D-Glucosamine or N-sulfate-6-O-sulfate-D-glucosamine

C=L-iduronic acid or, where present at a chain end, unsaturated uronic acid

D=N-acetyl-D-glucosamine or N-acetyl-6-O-sulfate-D-glucosamine

E=D-glucuronic acid

F=N-sulfate-3-O-sulfate-D-glucosamine or N-sulfate-3-O-sulfate-6-O-sulfate-D-glucosamine

G=2-O-sulfate-L-iduronic acid, and

H=N-sulfate-D-glucosamine or N-sulfate-6-O-sulfate-D-glucosamine.

3. The oligosaccharide of claim 1 wherein the N-sulfate-D-glucosamine is N-sulfate-3-O-sulfate-6-O-sulfate-D-glucosamine.

4. The oligosaccharide of claim 1 which includes a unit selected from the group consisting of N-acetyl-D-glucosamine, D-glucuronic acid, 2-O-sulfate-L-iduronic acid or N-sulfate-D-glucosamine.

5. The oligosaccharide of claim 1 which includes a unit selected from the group consisting of 2-O-sulfate-4,5 unsaturated uronic acid, N-sulfate-D-glucosamine or L-iduronic acid.

6. The oligosaccharide of claim 1 which includes a unit selected from the group consisting of N-sulfate-6-O-sulfate-D-glucosamine, L-iduronic acid, 2-O-sulfate-L-iduronic acid or N-sulfate-D-glucosamine.

7. The oligosaccharide of claim 2 wherein the saccharide sequence is selected from the group consisting of CDEFGH or ABCDEF.

8. The oligosaccharide of claim 2 wherein the saccharide sequence is selected from the group consisting of DEFGH.

9. The oligosaccharide of claim 1 which is the sodium, calcium or magnesium salt.

10. The oligosaccharide of claim 1 wherein the N-sulfate-D-glucosamine unit is at the reducing end of the oligosaccharide chain.

11. The oligosaccharide of claim 1 which comprises one N-acetyl-glucosamine saccharide moiety for every two or three N-sulfate-glucosamine saccharide moieties.

12. A therapeutic antithrombotic composition which has antithrombotic activity higher than that of heparin (as measured by the Yin-Wessler test) which composition comprises a therapeutically acceptable carrier and in a therapeutically effective amount, an oligosaccharide of claims 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, or 11.

13. The therapeutic composition of claim 12 in which the ratio of Yin-Wessler titer to USP titer is at least about 100.

14. The therapeutic composition of claim 12 in which the oligosaccharide has a Yin-Wessler titer of 100 to about 2,000 U/mg.

15. A therapeutic method for controlling thrombosis in a patient which comprises administering to said patient the therapeutic antithrombotic composition of claim 12 and controlling thrombosis.

16. The therapeutic method of claim 15 in which the administration of the composition is at periodic intervals.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc